Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents  

作　　者：Xiaofeng Mu Carolyn A.Cohen Daniel Leung Jaime S.Rosa Duque Samuel M.S.Cheng Yuet Chung Howard H.W.Wong Amos M.T.Lee Wing Yan Li Issan Y.S.Tam Jennifer H.Y.Lam Derek H.L.Lee Sau Man Chan Leo C.H.Tsang Karl C.K.Chan John K.C.Li Leo L.H.Luk Sara Chaothai Kelvin K.H.Kwan Nym Coco Chu Masashi Mori Trushar Jeevan Ahmed Kandeil Richard JWebby Wenwei Tu Sophie A.Valkenburg Malik Peiris Yu Lung Lau 

机构地区：[1]Department of Paediatrics and Adolescent Medicine,The University of Hong Kong,Hong Kong,China [2]HKU-Pasteur Research Pole,School of Public Health,The University of Hong Kong,Hong Kong,China [3]School of Public Health,The University of Hong Kong,Hong Kong,China [4]Research Institute for Bioresources and Biotechnology,Ishikawa Prefectural University,Nonoichi,Japan [5]Department of Infectious Diseases,St Jude Children’s Research Hospital,Memphis,TN,USA [6]Department of Microbiology and Immunology,Peter Doherty Institute for Infection and Immunity,University of Melbourne,Melbourne,VIC,Australia [7]Centre for Immunology&Infection C2i,Hong Kong,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第1期266-275,共10页信号转导与靶向治疗（英文）

基　　金：supported by the research grant COVID19F02 and COVID19F10 awarded to Y.L.L.by the Health Bureau,the Government of Hong Kong Special Administrative Region,which was not involved in the study design,data collection,laboratory assays,statistical computation,interpretation or final conclusions of this project;This research was also supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease(COVID-19);Hong Kong SAR(COVID190115);the Theme-based Research Scheme of the Research Grants Council of the Hong Kong Special Administrative Region,China(T11-705/21-N).

摘　　要：The high effectiveness of the third dose of BNT162b2 in healthy adolescents against Omicron BA.1 has been reported in some studies,but immune responses conferring this protection are not yet elucidated.In this analysis,our study(NCT04800133)aims to evaluate the humoral and cellular responses against wild-type and Omicron(BA.1,BA.2 and/or BA.5)SARS-CoV-2 before and after a third dose of BNT162b2 in healthy adolescents.At 5 months after 2 doses,S IgG,S IgG Fc receptor-binding,and neutralising antibody responses waned significantly,yet neutralising antibodies remained detectable in all tested adolescents and S IgG avidity increased from 1 month after 2 doses.The antibody responses and S-specific IFN-γ^(+)and IL-2^(+)CD8^(+)T cell responses were significantly boosted in healthy adolescents after a homologous third dose of BNT162b2.Compared to adults,humoral responses for the third dose were non-inferior or superior in adolescents.The S-specific IFN-γ^(+)and IL-2^(+)CD4^(+)and CD8^(+)T cell responses in adolescents and adults were comparable or non-inferior.Interestingly,after 3 doses,adolescents had preserved S IgG,S IgG avidity,S IgG FcγRIIIa-binding,against Omicron BA.2,as well as preserved cellular responses against BA.1 S and moderate neutralisation levels against BA.1,BA.2 and BA.5.Sera from 100 and 96%of adolescents tested at 1 and 5 months after two doses could also neutralise BA.1.Our study found high antibody and T cell responses,including potent cross-variant reactivity,after three doses of BNT162b2 vaccine in adolescents in its current formulation,suggesting that current vaccines can be protective against symptomatic Omicron disease.

关 键 词：doses NEUTRAL protective 

分 类 号：R563.1[医药卫生—呼吸系统] R392-33[医药卫生—内科学]